Gamida Cell Ltd. - Ordinary Shares (GMDA): Price and Financial Metrics


Gamida Cell Ltd. - Ordinary Shares (GMDA)

Today's Latest Price: $8.79 USD

0.44 (-4.77%)

Updated Jan 21 11:30am

Add GMDA to Watchlist
Sign Up

Overall POWR Rating

Sign Up to See Ratings...FREE!

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 484 in Biotech

See all "A" rated Strong Buy stocks

GMDA Stock Price Chart Interactive Chart >

Price chart for GMDA

GMDA Price/Volume Stats

Current price $8.79 52-week high $11.20
Prev. close $9.23 52-week low $2.60
Day low $8.63 Volume 422,628
Day high $9.37 Avg. volume 635,073
50-day MA $8.17 Dividend yield N/A
200-day MA $5.50 Market Cap 212.89M

Gamida Cell Ltd. - Ordinary Shares (GMDA) Company Bio

Gamida Cell Ltd. is a clinical stage biopharmaceutical company, which engages in the development of cell therapies that are designed to cure cancer and rare serious hematologic diseases. Its products pipeline include NiCord and NAM-NK. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.

Most Popular Stories View All

• How to Outperform the Stock Market in 2021

• Is Shopify a Smart Buy for 2021?

• 3 Auto Stocks to Buy Instead of Tesla: Ford, GM, and Tata Motors

• Better Buy: Marathon Patent Group vs. Canaan

• 3 Lesser-Known Biotech Stocks that are Surging

View All Top Stories

GMDA Latest News Stream

Event/Time News Detail
Loading, please wait...
View All GMDA News

GMDA Latest Social Stream

Loading social stream, please wait...

View Full GMDA Social Stream

Latest GMDA News From Around the Web

Below are the latest news stories about Gamida Cell Ltd that investors may wish to consider to help them evaluate GMDA as an investment opportunity.

5 Low-Priced, Small-Cap Stocks Poised for Big Gains in 2021

Want to make it big in the new year? Then think small, says Real Money columnist James 'Rev Shark' DePorre.

Yahoo | January 15, 2021

Gamida Cell to Present Full Data from Phase 3 Study of Omidubicel at TCT, the Combined Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that the full results of the Phase 3 clinical trial of omidubicel will be presented for the first time at the TCT Meetings, the Transplantation & Cellular Therapy Meetings of the American Society of Transplantation and Cellular Therapy (ASTCT) and Center for International Blood & Marrow Transplant Research (CIBMTR), which is being held virtually from February 8–12, 2021.

Yahoo | January 11, 2021

Gamida Cell Announces Closing of $75 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that its previously announced public offering closed on December 21, 2020. The total number of ordinary shares sold by the Company in the offering was 9,343,750, inclusive of the full exercise of the underwriters’ option to purchase up to an additional 1,218,750 shares, at the public offering price of $8.00 per share, less underwriting discounts and commissions. After giving effect to the option closing, the shares sold by the Company resulted in aggregate gross proceeds to the Company of $74.75 million before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.

Yahoo | December 21, 2020

Gamida Cell Announces Pricing of $65 Million Public Offering of Ordinary Shares

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced the pricing of a follow-on public offering of 8,125,000 ordinary shares at a public offering price of $8.00 per share for aggregate gross proceeds of $65.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition, Gamida Cell has granted the underwriters a 30-day option to purchase up to an additional 1,218,750 ordinary shares at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on or about December 21, 2020, subject to satisfaction of customary closing conditions.

Yahoo | December 17, 2020

Gamida Cell Announces Launch of Public Offering of Ordinary Shares

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced the launch of a follow-on public offering of its ordinary shares. In addition, Gamida Cell expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the ordinary shares to be sold in the offering on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed. All of the shares in the offering are to be sold by Gamida Cell.

Yahoo | December 17, 2020

Read More 'GMDA' Stories Here

GMDA Price Returns

1-mo -4.77%
3-mo 56.41%
6-mo 99.32%
1-year 89.44%
3-year N/A
5-year N/A
YTD 4.77%
2020 95.12%
2019 -56.74%
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7116 seconds.